Functional analysis of a novel nonsense variant c.91A>T of the gene in a Chinese family with X-linked recessive autosomal spondyloepiphyseal dysplasia tarda.

Front Genet

Henan Provincial People's Hospital, Medical Genetics Institute of Henan Province, Henan Provincial Key Laboratory of Genetic Diseases and Functional Genomics, People's Hospital of Zhengzhou University, Zhengzhou, China.

Published: August 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Spondyloepiphyseal dysplasia tarda (SEDT) is a condition involving late-onset, X-linked recessive skeletal dysplasia caused by mutations in the gene. In this paper, we identified a novel nonsense variant in a SEDT pedigree and analyzed the function of the variant in an attempt to explain the new pathogenesis of the TRAPPC2 protein in SEDT. Briefly, DNA and RNA samples from the peripheral blood of SEDT individuals were prepared. The causative variant in the Chinese SEDT family was identified by clinic whole-exome sequencing analysis. Then, we observed the mRNA expression of in patients and the mutant TRAPPC2 level and analyzed the protein stability and subcellular distribution by cell fluorescence and Western blotting. We also investigated the effect of knockdown on the expression and secretion of COL2A1 in SW1353 cells or primary human chondrocytes. Herein, we found a nonsense variant, c.91A>T, of the gene in the pedigree. mRNA expression levels were significantly decreased in the available peripheral blood cell samples of two affected patients. An study showed that the mutant plasmid exhibited significantly lower mRNA and protein of , and the mutant protein changed its membrane distribution. knockdown resulted in decreased expression and collagen II secretions. Our data indicate that the novel nonsense variant, c.91A>T, of the gene is the cause of SEDT in this pedigree. The variant results in a lowered expression of TRAPPC2 and then affects the expression and collagen II secretions, which may explain the mechanism of loss of function of the variant.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492639PMC
http://dx.doi.org/10.3389/fgene.2023.1216592DOI Listing

Publication Analysis

Top Keywords

nonsense variant
16
novel nonsense
12
variant c91a>t
12
c91a>t gene
12
variant
8
x-linked recessive
8
spondyloepiphyseal dysplasia
8
dysplasia tarda
8
sedt pedigree
8
function variant
8

Similar Publications

CAMTA1 Nonsense Variant Inherited From Asymptomatic Mother: Extremely Variable Expressivity in Congenital Ataxia.

Clin Genet

September 2025

Department of Physical Medicine and Rehabilitation, Jeju National University Hospital, College of Medicine, Jeju National University, Jeju, Republic of Korea.

Complete absence of symptoms in a mother carrying CAMTA1 c.1544C>A contrasts with severe congenital ataxia in her son. Early intervention at 16 months led to exceptional recovery (GMFM-88: 56.

View Article and Find Full Text PDF

A Novel Homozygous Nonsense Pathogenic Variant of the CPAMD8 Gene Associated With Congenital Microcoria.

Clin Genet

September 2025

Eye Hospital, the First Affiliated Hospital of Harbin Medical University, Key Laboratory of Basic and Clinical Research of Heilongjiang Province, Harbin, Heilongjiang Province, People's Republic of China.

Congenital microcoria (MCOR) is a rare inherited ocular disorder. Here, we describe a novel nonsense variant in the CPAMD8 gene in a patient with MCOR. We conducted a comprehensive clinical examination of a patient diagnosed with MCOR and performed whole-exome sequencing to identify potential pathogenic variants.

View Article and Find Full Text PDF

Neutral Lipid Storage Disease with Myopathy (NLSDM) is a rare lipid metabolism disorder caused by impaired Adipose Triglyceride Lipase (ATGL) activity, leading to neutral lipid accumulation in various tissues. It typically manifests with progressive skeletal myopathy, with an onset of around 35 years. In addition, some patients develop cardiomyopathy and liver dysfunction.

View Article and Find Full Text PDF

Clotting factor concentrate (CFC), used to treat and prevent bleeding in hemophilia, is rendered ineffective if clotting factor neutralizing antibodies (inhibitors) develop. Inhibitors occur most often in children, early in treatment. The American Thrombosis and Hemostasis Network (ATHN) 8: US Cohort Study of Previously Untreated Patients (PUPs) with Congenital Hemophilia, conducted in children born in 2010 to 2020 with severe or moderate hemophilia, was designed to determine the percentage of participants who developed a confirmed, clinically significant inhibitor within the first 50 CFC exposure days (EDs).

View Article and Find Full Text PDF

Numerous genetic conditions are represented within the biochemical pathway for de novo cholesterol biosynthesis. Among the emerging disease-gene associations is CYP51A1, encoding a lanosterol demethylase enzyme. Biallelic variants in CYP51A1 have been associated with congenital cataracts and variable liver disease but an appreciation of genotype/phenotype correlation is lacking due to the limited number of patients described.

View Article and Find Full Text PDF